"We have a few more weeks to be sure to demonstrate causality, but the link between Zika and Guillain-Barre is highly probable," Marie-Paule Kieny, WHO Assistant Director-General for Health Systems and Innovation, told a news briefing.
Kieny said U.S. government scientists and an Indian biotechnology company were currently frontrunners in vaccine development, although it would take at least 18 months to start large-scale clinical trials of candidate shots.
"Two vaccine candidates seem to be more advanced: a DNA vaccine from the U.S. National Institutes for Health and an inactivated product from Bharat Biotech in India," she said.
More about:
